Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Interest & Investment Income (2016 - 2025)

KalVista Pharmaceuticals' Interest & Investment Income history spans 11 years, with the latest figure at $2.0 million for Q2 2025.

  • For Q2 2025, Interest & Investment Income rose 31.66% year-over-year to $2.0 million; the TTM value through Apr 2025 reached $6.6 million, up 68.25%, while the annual FY2025 figure was $6.4 million, 65.17% up from the prior year.
  • Interest & Investment Income for Q2 2025 was $2.0 million at KalVista Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.0 million in Q2 2025 and bottomed at $137000.0 in Q1 2021.
  • The 4-year median for Interest & Investment Income is $1.1 million (2023), against an average of $1.1 million.
  • The largest annual shift saw Interest & Investment Income tumbled 63.17% in 2021 before it skyrocketed 83.32% in 2024.
  • A 4-year view of Interest & Investment Income shows it stood at $137000.0 in 2021, then surged by 466.42% to $776000.0 in 2023, then soared by 75.0% to $1.4 million in 2024, then skyrocketed by 46.69% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Interest & Investment Income are $2.0 million (Q2 2025), $1.4 million (Q4 2024), and $1.7 million (Q3 2024).